Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0RYQBT
|
|||||
---|---|---|---|---|---|---|
ADC Name |
Anti-FOLR1-Ala-Ala-IGN
|
|||||
Synonyms |
Anti FOLR1 Ala Ala IGN
Click to Show/Hide
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 4 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Cervical cancer [ICD11:2C77]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
Drug-to-Antibody Ratio |
1.6
|
|||||
Antibody Name |
Anti-FOLR1 mAb
|
Antibody Info | ||||
Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
Payload Name |
Indolinobenzodiazepine dimer
|
Payload Info | ||||
Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
Linker Name |
Ala-Ala dipeptide
|
Linker Info | ||||
Conjugate Type |
Random conjugation conjugation through nucleophilic lysines.
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Standard Type | Value | Units | Cell Line | Disease Model |
---|---|---|---|---|
Tumor Growth Inhibition value (TGI) |
≈ 100
|
%
|
NCI-H2110 cells
|
Lung non-small cell carcinoma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 35) | Positive FOLR1 expression (FOLR1+++/++) | ||
Method Description |
Animals with established tumors were randomized into six mice per treatment group and dosed with a single i.v. dose of vehicle or IGN ADCs at either 3 ug/kg drug dose.
|
||||
In Vivo Model | NCI-H2110 CDX model | ||||
In Vitro Model | Lung non-small cell carcinoma | NCI-H2110 cells | CVCL_1530 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Effective Concentration (EC50) | 5.00 pM | Positive EGFR expression (EGFR+++/++) | ||
Method Description |
Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
|
||||
In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Effective Concentration (EC50) | 9.30 pM | Positive EGFR expression (EGFR+++/++) | ||
Method Description |
Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
|
||||
In Vitro Model | Ovarian endometrioid adenocarcinoma | IGROV-1 cells | CVCL_1304 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Effective Concentration (EC50) | 30.00 pM | Positive EGFR expression (EGFR+++/++) | ||
Method Description |
Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
|
||||
In Vitro Model | Invasive breast carcinoma | T-47D cells | CVCL_0553 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Effective Concentration (EC50) | 30.00 pM | Positive EGFR expression (EGFR+++/++) | ||
Method Description |
Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
|
||||
In Vitro Model | Ovarian adenocarcinoma | OV-90 cells | CVCL_3768 | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.20 nM | Positive EGFR expression (EGFR+++/++) | ||
Method Description |
Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
|
||||
In Vitro Model | Lung non-small cell carcinoma | NCI-H2110 cells | CVCL_1530 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.